Подходы к противоопухолевой терапии на основе модуляции метилирования ДНК

Подходы к противоопухолевой терапии на основе модуляции метилирования ДНК

Автор: Максимова В.П., Макусь Ю.В., Попова В.Г., Усалка О.Г., Белицкий Г.А., Якубовская М.Г., Кирсанов К.И.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 4 т.23, 2024 года.

Бесплатный доступ

Актуальность. Метилирование ДНК - важнейший механизм эпигенетической регуляции транскрипции. Нарушения в механизме метилирования ДНК ассоциированы с различными злокачественными новообразованиями (ЗНО), такими как острый миелоидный лейкоз, рак молочной железы, рак предстательной железы и др. Влияние на функциональное состояние ферментов ДНК-метилтрансфераз (DNMTs) и белков семейства ТЕТ (TETs), регулирующих метилирование и деметилирование ДНК, является основой подхода эпигенетической противоопухолевой терапии. В обзоре рассматриваются проблемы и перспективы применения нуклеозидных и ненуклеозидных ингибиторов DNMTs, а также ингибиторов TETs. Представлена оценка результатов клинических исследований эффективности ингибиторов DNMTs, применяемых индивидуально и в составе комбинированной химиотерапии, проведенных за последние 15 лет. Материал и методы. Поиск источников проводили в системах PubMed, ScienceDirect, Web of Science, eLibrary, CyberLeninka. В анализе использовано более 700 публикаций, в обзор включены преимущественно работы последних 10 лет. Ряд статей, опубликованных ранее 2015 г., использован для исторической справки.

Еще

Противоопухолевая терапия, метилирование днк, ингибиторы dnmts, ингибиторы tets, клинические испытания

Короткий адрес: https://sciup.org/140307080

IDR: 140307080   |   DOI: 10.21294/1814-4861-2024-23-4-125-140

Список литературы Подходы к противоопухолевой терапии на основе модуляции метилирования ДНК

  • Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1): 31-46. https://doi.org/10.1158/2159-8290.CD-21-1059.
  • Cheng Y., He C., Wang M., Ma X., Mo F., Yang S., Han J., Wei X. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019; 4: 62. https://doi.org/10.1038/s41392-019-0095-0.
  • Maksimova V.P., Usalka O.G., Makus' Yu.V., Popova V.G., Trapeznikova E.S., Khairieva G.I., Sagitova G.R., Zhidkova E.M., Prus A.Yu., Yakubovskaya M.G., Kirsanov K.I. Narushenie metilirovaniya DNK pri zlokachestvennykh novoobrazovaniyakh. Uspekhi molekulyarnoi onkologii. 2022; 9(4): 24-40. https://doi.org/10.17650/2313-805X-2022-9-4-24-40.
  • Kohli R.M., Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013; 502(7472): 472-9. https://doi.org/10.1038/nature12750.
  • Takeshima H., Niwa T., Yamashita S., Takamura-Enya T., Iida N., Wakabayashi M., Nanjo S., Abe M., Sugiyama T., Kim Y.J., Ushijima T. TET repression and increased DNMT activity synergistically induce aberrant DNA methylation. J Clin Invest. 2020; 130(10): 5370-9. https://doi.org/10.1172/JCI124070.
  • Liu X.L., Liu H.Q., Li J., Mao C.Y., He J.T., Zhao X. Role of epigenetic in leukemia: From mechanism to therapy. Chem Biol Interact. 2020; 317. https://doi.org/10.1016/j.cbi.2020.108963.
  • Stresemann C., Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008; 123(1): 8-13. https://doi.org/10.1002/ijc.23607.
  • Yang X., Lay F., Han H., Jones P.A. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci. 2010; 31(11): 536-46. https://doi.org/10.1016/j.tips.2010.08.001.
  • Gu X., Tohme R., Tomlinson B., Sakre N., Hasipek M., Durkin L., Schuerger C., Grabowski D., Zidan A.M., Radivoyevitch T., Hong C., Carraway H., Hamilton B., Sobecks R., Patel B., Jha B.K., Hsi E.D., Maciejewski J., Saunthararajah Y. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia. 2021; 35(4): 1023-36. https://doi.org/10.1038/s41375-020-1003-x.
  • Malik P., Cashen A.F. Decitabine in the treatment of acute myeloid leukemia in elderly patients. Cancer Manag Res. 2014; 6: 53-61. https://doi.org/10.2147/CMAR.S40600.
  • Kaminskas E., Farrell A.T., Wang Y.C., Sridhara R., Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005; 10(3): 176-82. https://doi.org/10.1634/theoncologist.10-3-176.
  • Tallman M.S., Wang E.S., Altman J.K., Appelbaum F.R., Bhatt V.R., Bixby D., Coutre S.E., De Lima M., Fathi A.T., Fiorella M., Foran J.M., Hall A.C., Jacoby M., Lancet J., LeBlanc T.W., Mannis G., Marcucci G., Martin M.G., Mims A., O'Donnell M.R., Olin R., Peker D., Perl A., Pollyea D.A., Pratz K., Prebet T., Ravandi F., Shami P.J., Stone R.M., Strickland S.A., Wieduwilt M., Gregory K.M.; OCN; Hammond L., Ogba N. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(6): 721-49. https://doi.org/10.6004/jnccn.2019.0028.
  • Savchenko V.G., Parovichnikova E.N., Afanas'ev B.V., Gritsaev S.V., Semochkin S.V., Bondarenko S.N., Troitskaya V.V., Sokolov A.N., Kuz'mina L.A., Klyasova G.A., Gaponova T.V., Baranova O.Yu., Lapin V.A., Konstantinova T.S., Samoilova O.S., Kaporskaya T.S., Shatokhin S.A. Klinicheskie rekomendatsii po diagnostike i lecheniyu ostrykh limfoblastnykh leikozov vzroslykh. Natsional'noe gematologicheskoe obshchestvo. 2014. 65 s.
  • Wei A.H., Döhner H., Pocock C., Montesinos P., Afanasyev B., Dombret H., Ravandi F., Sayar H., Jang J.H., Porkka K., Selleslag D., Sandhu I., Turgut M., Giai V., Ofran Y., Kizil Çakar M., Botelho de Sousa A., Rybka J., Frairia C., Borin L., Beltrami G., Čermák J., Ossenkoppele G.J., La Torre I., Skikne B., Kumar K., Dong Q., Beach C.L., Roboz G.J., for the QUAZAR AML-001 Trial Investigators†. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med. 2020; 383(26): 2526-37. https://doi.org/10.1056/NEJMoa2004444.
  • Montesinos P., Recher C., Vives S., Zarzycka E., Wang J., Bertani G., Heuser M., Calado R.T., Schuh A.C., Yeh S.P., Daigle S.R., Hui J., Pandya S.S., Gianolio D.A., de Botton S., Döhner H. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. N Engl J Med. 2022; 386(16): 1519-31. https://doi.org/10.1056/NEJMoa2117344.
  • Niemeyer C.M., Flotho C., Lipka D.B., Starý J., Rössig C., Baruchel A., Klingebiel T., Micalizzi C., Michel G., Nysom K., Rives S., Schmugge Liner M., Zecca M., Schönung M., Baumann I., Nöllke P., Benettaib B., Biserna N., Poon J., Simcock M., Patturajan M., Menezes D., Gaudy A., van den Heuvel-Eibrink M.M., Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML001 trial. Blood Adv. 2021; 5(14): 2901-8. https://doi.org/10.1182/bloodadvances.2020004144.
  • Jabbour E., Issa J.P., Garcia-Manero G., Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008; 112(11): 2341-51. https://doi.org/10.1002/cncr.23463.
  • Briski R., Garcia-Manero G., Kantarjian H., Ravandi F. The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia. Ther Adv Hematol. 2023; 14. https://doi.org/10.1177/20406207231205429.
  • Pollyea D.A., Winters A., McMahon C., Schwartz M., Jordan C.T., Rabinovitch R., Abbott D., Smith C.A., Gutman J.A. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022; 57(2): 160-6. https://doi.org/10.1038/s41409-021-01476-7.
  • Sekeres M.A., Watts J., Radinoff A., Sangerman M.A., Cerrano M., Lopez P.F., Zeidner J.F., Campelo M.D., Graux C., Liesveld J., Selleslag D., Tzvetkov N., Fram R.J., Zhao D., Bell J., Friedlander S., Faller D.V., Adès L. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia. 2021; 35(7): 2119-24. https://doi.org/10.1038/s41375-021-01125-4. Erratum in: Leukemia. 2021; 35(12): 3637. https://doi.org/10.1038/s41375-021-01473-1.
  • DiNardo C.D., Schuh A.C., Stein E.M., Montesinos P., Wei A.H., de Botton S., Zeidan A.M., Fathi A.T., Kantarjian H.M., Bennett J.M., Frattini M.G., Martin-Regueira P., Lersch F., Gong J., Hasan M., Vyas P., Döhner H. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221- AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021; 22(11): 1597-608. https://doi.org/10.1016/S1470-2045(21)00494-0.
  • Ohanian M., Garcia-Manero G., Levis M., Jabbour E., Daver N., Borthakur G., Kadia T., Pierce S., Burger J., Richie M.A., Patel K., Andreeff M., Estrov Z., Cortes J., Kantarjian H., Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018; 93(9): 1136-41. https://doi.org/10.1002/ajh.25198.
  • Hu J., Wang X., Chen F., Ding M., Dong M., Yang W., Yin M., Wu J., Zhang L., Fu X., Sun Z., Li L., Wang X., Li X., Guo S., Zhang D., Lu X., Leng Q., Zhang M., Zhu L., Zhang X., Chen Q. Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. Front Oncol. 2021; 11. https://doi.org/10.3389/fonc.2021.687374.
  • Buocikova V., Tyciakova S., Pilalis E., Mastrokalou C., Urbanova M., Matuskova M., Demkova L., Medova V., Longhin E.M., Rundén-Pran E., Dusinska M., Rios-Mondragon I., Cimpan M.R., Gabelova A., Soltysova A., Smolkova B., Chatziioannou A. Decitabine-induced DNA methylationmediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression. Front Pharmacol. 2022; 13. https://doi.org/10.3389/fphar.2022.991751.
  • Champion C., Guianvarc’h D., Sénamaud-Beaufort C., Jurkowska R.Z., Jeltsch A., Ponger L., Arimondo P.B., Guieysse-Peugeot A.L. Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine. PLoS One. 2010; 5(8). https://doi.org/10.1371/journal.pone.0012388.
  • Lu Y., Chan Y.T., Tan H.Y., Li S., Wang N., Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. 2020; 19(1): 79. https://doi.org/10.1186/s12943-020-01197-3.
  • Cheng J.C., Yoo C.B., Weisenberger D.J., Chuang J., Wozniak C., Liang G., Marquez V.E., Greer S., Orntoft T.F., Thykjaer T., Jones P.A. Preferential response of cancer cells to zebularine. Cancer Cell. 2004; 6(2): 151-8. https://doi.org/10.1016/j.ccr.2004.06.023.
  • Takemura Y., Satoh M., Hatanaka K., Kubota S. Zebularine exerts its antiproliferative activity through S phase delay and cell death in human malignant mesothelioma cells. Biosci Biotechnol Biochem. 2018; 82(7): 1159-64. https://doi.org/10.1080/09168451.2018.1459466.
  • Cheng J.C., Weisenberger D.J., Gonzales F.A., Liang G., Xu G.L., Hu Y.G., Marquez V.E., Jones P.A. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol. 2004; 24(3): 1270-8. https://doi.org/10.1128/MCB.24.3.1270-1278.2004.
  • Lemaire M., Momparler L.F., Raynal N.J., Bernstein M.L., Momparler R.L. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol. 2009; 63(3): 411-6. https://doi.org/10.1007/s00280-008-0750-6.
  • Fulkerson C.M., Dhawan D., Jones D.R., Marquez V.E., Jones P.A., Wang Z., Wu Q., Klaunig J.E., Fourez L.M., Bonney P.L., Knapp D.W. Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs. Vet Comp Oncol. 2017; 15(1): 226-36. https://doi.org/10.1111/vco.12159.
  • Holleran J.L., Eiseman J.L., Parise R.A., Kummar S., Beumer J.H. LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma. J Pharm Biomed Anal. 2016; 129: 359-66. https://doi.org/10.1016/j.jpba.2016.07.027.
  • Guo D., Myrdal P.B., Karlage K.L., O’Connell S.P., Wissinger T.J., Tabibi S.E., Yalkowsky S.H. Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination. AAPS PharmSciTech. 2010; 11(1): 247-52. https://doi.org/10.1208/s12249-010-9383-2.
  • Holleran J.L., Beumer J.H., McCormick D.L., Johnson W.D., Newman E.M., Doroshow J.H., Kummar S., Covey J.M., Davis M., Eiseman J.L. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans. Cancer Chemother Pharmacol. 2015; 76(4): 803-11. https://doi.org/10.1007/s00280-015-2857-x.
  • Coyne G.O.', Wang L., Zlott J., Juwara L., Covey J.M., Beumer J.H., Cristea M.C., Newman E.M., Koehler S., Nieva J.J., Garcia A.A., Gandara D.R.,Miller B., Khin S., Miller S.B., Steinberg S.M., Rubinstein L., Parchment R.E., Kinders R.J., Piekarz R.L., Kummar S., Chen A.P., Doroshow J.H. Intravenous 5-fluoro-2’-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020; 85(5): 979-93. https://doi.org/10.1007/s00280-020-04073-5.
  • Brueckner B., Rius M., Markelova M.R., Fichtner I., Hals P.A., Sandvold M.L., Lyko F. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol Cancer Ther. 2010; 9(5): 1256-64. https://doi.org/10.1158/1535-7163.MCT-09-1202.
  • Rius M., Stresemann C., Keller D., Brom M., Schirrmacher E., Keppler D., Lyko F. Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther. 2009; 8(1): 225-31. https://doi.org/10.1158/1535-7163.MCT-08-0743.
  • Byun H.M., Choi S.H., Laird P.W., Trinh B., Siddiqui M.A., Marquez V.E., Yang A.S. 2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5 -azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Lett. 2008; 266(2): 238-48. https://doi.org/10.1016/j.canlet.2008.02.069.
  • Srivastava P., Paluch B.E., Matsuzaki J., James S.R., CollamatLai G., Karbach J., Nemeth M.J., Taverna P., Karpf A.R., Griffiths E.A. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res. 2014; 38(11): 1332-41. https://doi.org/10.1016/j.leukres.2014.09.001.
  • Garcia-Manero G., Roboz G., Walsh K., Kantarjian H., Ritchie E., Kropf P., O’Connell C., Tibes R., Lunin S., Rosenblat T., Yee K., Stock W., Griffiths E., Mace J., Podoltsev N., Berdeja J., Jabbour E., Issa J.J., Hao Y., Keer H.N., Azab M., Savona M.R. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019; 6(6): 317-27. https://doi.org/10.1016/S2352-3026(19)30029-8.
  • Oza A.M., Matulonis U.A., Secord A.A., Nemunaitis J., Roman L.D., Blagden S.P., Banerjee S., McGuire W.P., Ghamande S., Birrer M.J., Fleming G.F., Markham M.J., Hirte H.W., Provencher D.M., Basu B., Kristeleit R., Armstrong D.K., Schwartz B., Braly P., Hall G.D., Nephew K.P., Jueliger S., Oganesian A., Naim S., Hao Y., Keer H., Azab M., Matei D. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020; 26(5): 1009-16. https://doi.org/10.1158/1078-0432.CCR-19-1638.
  • Chen S., Xie P., Cowan M., Huang H., Cardenas H., Keathley R., Tanner E.J., Fleming G.F., Moroney J.W., Pant A., Akasha A.M., Davuluri R.V., Kocherginsky M., Zhang B., Matei D. Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. J Clin Invest. 2022; 132(14). https://doi.org/10.1172/JCI158800.
  • Crabb S.J., Danson S., Catto J.W.F., Hussain S., Chan D., Dunkley D., Downs N., Marwood E., Day L., Saunders G., Light M., Whitehead A., Ellis D., Sarwar N., Enting D., Birtle A., Johnson B., Huddart R., Griffiths G. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). Clin Cancer Res. 2021; 27(7): 1882-92. https://doi.org/10.1158/1078-0432.CCR-20-3946.
  • Brueckner B., Lyko F. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci. 2004; 25(11): 551-4. https://doi.org/10.1016/j.tips.2004.09.004.
  • Ou Y., Zhang Q., Tang Y., Lu Z., Lu X., Zhou X., Liu C. DNA methylation enzyme inhibitor RG108 suppresses the radioresistance of esophageal cancer. Oncol Rep. 2018; 39(3): 993-1002. https://doi.org/10.3892/or.2018.6210.
  • Yang L., Hou J., Cui X.H., Suo L.N., Lv Y.W. RG108 induces the apoptosis of endometrial cancer Ishikawa cell lines by inhibiting the expression of DNMT3B and demethylation of HMLH1. Eur Rev Med Pharmacol Sci. 2017; 21(22): 5056-64. https://doi.org/10.26355/eurrev_201711_13818.
  • Lee B.H., Yegnasubramanian S., Lin X., Nelson W.G. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem. 2005; 280(49): 40749-56. https://doi.org/10.1074/jbc.M505593200.
  • Villar-Garea A., Fraga M.F., Espada J., Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003; 63(16): 4984-9.
  • Sabit H., Samy M.B., Said O.A., El-Zawahri M.M. Procaine Induces Epigenetic Changes in HCT116 Colon Cancer Cells. Genet Res Int. 2016. https://doi.org/10.1155/2016/8348450.
  • Li Y.C., Wang Y., Li D.D., Zhang Y., Zhao T.C., Li C.F. Procaine is a specific DNA methylation inhibitor with anti-tumor effect for human gastric cancer. J Cell Biochem. 2018; 119(2): 2440-9. https://doi.org/10.1002/jcb.26407.
  • Ma X.W., Li Y., Han X.C., Xin Q.Z. The effect of low dosage of procaine on lung cancer cell proliferation. Eur Rev Med Pharmacol Sci. 2016; 20(22): 4791-5.
  • Gao Z., Xu Z., Hung M.S., Lin Y.C., Wang T., Gong M., Zhi X., Jablons D.M., You L. Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells. Oncol Rep. 2009; 22(6): 1479-84. https://doi.org/10.3892/or_00000590.
  • Uetrecht J.P., Freeman R.W., Woosley R.L. The implications of procainamide metabolism to its induction of lupus. Arthritis Rheum. 1981; 24(8): 994-1003. https://doi.org/10.1002/art.1780240803.
  • Paşa S., Erdogan O., Cevik O. Design, synthesis and investigation of procaine based new Pd complexes as DNA methyltransferase inhibitor on gastric cancer cells. Inorg Chem Comm. 2021; 132. https://doi.org/10.1016/j.inoche.2021.108846.
  • Tanaka H., Marumo H., Nagai T., Okada M., Taniguchi K. Nanaomycins, new antibiotics produced by a strain of Streptomyces. III. A new component, nanaomycin C, and biological activities of nanaomycin derivatives. J Antibiot (Tokyo). 1975; 28(12): 925-30. https://doi.org/10.7164/antibiotics.28.925.
  • Kormanec J., Novakova R., Csolleiova D., Feckova L., Rezuchova B., Sevcikova B., Homerova D. The antitumor antibiotic mithramycin: new advanced approaches in modification and production. Appl Microbiol Biotechnol. 2020; 104(18): 7701-21. https://doi.org/10.1007/s00253-020-10782-x.
  • Kuck D., Caulfield T., Lyko F., Medina-Franco J.L. Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther. 2010; 9(11): 3015-23. https://doi.org/10.1158/1535-7163.MCT-10-0609.
  • Liu P.Y., Sokolowski N., Guo S.T., Siddiqi F., Atmadibrata B., Telfer T.J., Sun Y., Zhang L., Yu D., Mccarroll J., Liu B., Yang R.H., Guo X.Y., Tee A.E., Itoh K., Wang J., Kavallaris M., Haber M., Norris M.D., Cheung B.B., Byrne J.A., Ziegler D.S., Marshall G.M., Dinger M.E., Codd R., Zhang X.D., Liu T. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. Oncotarget. 2016; 7(48): 79217-32. https://doi.org/10.18632/oncotarget.12640.
  • Lin R.K., Hsu C.H., Wang Y.C. Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells. Anticancer Drugs. 2007; 18(10): 1157-64. https://doi.org/10.1097/CAD.0b013e3282a215e9.
  • Arce C., Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Candelaria M., Dueñnas-Gonzalez A. Hydralazine target: from blood vessels to the epigenome. J Transl Med. 2006; 4: 10. https://doi.org/10.1186/1479-5876-4-10.
  • Graça I., Sousa E.J., Costa-Pinheiro P., Vieira F.Q., TorresFerreira J., Martins M.G., Henrique R., Jerónimo C. Anti-neoplastic properties of hydralazine in prostate cancer. Oncotarget. 2014; 5(15): 5950-64. https://doi.org/10.18632/oncotarget.1909.
  • Singh N., Dueñas-González A., Lyko F., Medina-Franco J.L. Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. ChemMedChem. 2009; 4(5): 792-9. https://doi.org/10.1002/cmdc.200900017.
  • Kumanishi S., Yamanegi K., Nishiura H., Fujihara Y., Kobayashi K., Nakasho K., Futani H., Yoshiya S. Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells. Int J Oncol. 2019; 55(1): 167-78. https://doi.org/10.3892/ijo.2019.4811.
  • Bauman J., Shaheen M., Verschraegen C.F., Belinsky S.A., Houman Fekrazad M., Lee F.C., Rabinowitz I., Ravindranathan M., Jones D.V. Jr. A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers. Transl Oncol. 2014; 7(3): 349-54. https://doi.org/10.1016/j.tranon.2014.03.001.
  • Espinoza-Zamora J.R., Labardini-Méndez J., Sosa-Espinoza A., López-González C., Vieyra-García M., Candelaria M., Lozano-Zavaleta V., Toledano-Cuevas D.V., Zapata-Canto N., Cervera E., Dueñas-González A. Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study. Expert Opin Investig Drugs. 2017; 26(4): 481-7. https://doi.org/10.1080/13543784.2017.1291630. Erratum in: Expert Opin Investig Drugs. 2017; 26(4): 523. https://doi.org/10.1080/13543784.2017.1306178.
  • Maiti A., Daver N.G. Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions. J Clin Oncol. 2022; 40(34): 3994-7. https://doi.org/10.1200/JCO.22.01505.
  • Qiang W., Jin T., Yang Q., Liu W., Liu S., Ji M., He N., Chen C., Shi B., Hou P. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells. J Biomed Nanotechnol. 2014; 10(7): 1249-58. https://doi.org/10.1166/jbn.2014.1862.
  • Teoh P.J., Bi C., Sintosebastian C., Tay L.S., Fonseca R., Chng W.J. PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. Oncotarget. 2016; 7(38): 61806-19. https://doi.org/10.18632/oncotarget.11241.
  • Fujihara K.M., Zhang B.Z., Jackson T.D., Ogunkola M.O., Nijagal B., Milne J.V., Sallman D.A., Ang C.S., Nikolic I., Kearney C.J., Hogg S.J., Cabalag C.S., Sutton V.R., Watt S., Fujihara A.T., Trapani J.A., Simpson K.J., Stojanovski D., Leimkühler S., Haupt S., Phillips W.A., Clemons N.J. Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction. Sci Adv. 2022; 8(37). https://doi.org/10.1126/sciadv.abm9427.
  • Amirtharaj F., Venkatesh G.H., Wojtas B., Nawafleh H.H., Mahmood A.S., Nizami Z.N., Khan M.S., Thiery J., Chouaib S. p53 reactivating small molecule PRIMA-1MET/APR-246 regulates genomic instability in MDA-MB-231 cells. Oncol Rep. 2022; 47(4): 85. https://doi.org/10.3892/or.2022.8296.
  • Fransson Å., Glaessgen D., Alfredsson J., Wiman K.G., BajalicaLagercrantz S., Mohell N. Strong synergy with APR-246 and DNAdamaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. J Ovarian Res. 2016; 9(1): 27. https://doi.org/10.1186/s13048-016-0239-6.
  • Sallman D.A., Dezern A.E., Steensma D., Sweet K.L., Cluzeau T., Sekeres M., Garcia-Manero G., Roboz G.J., McLemore A.F., McGraw K.L., Puskas J., Zhang L., Bhagat C.K., Yao J., Ali N.A., Padron E., Tell R., Lancet J.E., Fenaux P., List A., Komrokji R.S. Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Adv. 2018; 132 (s1). https://doi.org/10.1182/blood-2018-99-119990.
  • Sun N., Zhang J., Zhang C., Zhao B., Jiao A. DNMTs inhibitor SGI-1027 induces apoptosis in Huh7 human hepatocellular carcinoma cells. Oncol Lett. 2018; 16(5): 5799-806. https://doi.org/10.3892/ol.2018.9390.
  • García-Domínguez P., Dell'aversana C., Alvarez R., Altucci L., de Lera A.R. Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line. Bioorg Med Chem Lett. 2013; 23(6): 1631-5. https://doi.org/10.1016/j.bmcl.2013.01.085.
  • Kelly G.S. Quercetin. Monograph. Altern Med Rev. 2011; 16(2): 172-94.
  • Bilyk O.V., Rybal'chenko V.K., Romanyuk B.P. Bioflavonoid kvertsetin i perspektivy ego ispol'zovaniya v meditsine. Zagal'na patologiya ta patologichna fiziologiya. 2007; 2(1): 4-9.
  • Alvarez M.C., Maso V., Torello C.O., Ferro K.P., Saad S.T.O. The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes. Clin Epigenetics. 2018; 10(1): 139. https://doi.org/10.1186/s13148-018-0563-3.
  • Kedhari Sundaram M., Hussain A., Haque S., Raina R., Afroze N. Quercetin modifies 5’CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells. J Cell Biochem. 2019; 120(10): 18357-69. https://doi.org/10.1002/jcb.29147.
  • Almatroodi S.A., Almatroudi A., Khan A.A., Alhumaydhi F.A., Alsahli M.A., Rahmani A.H. Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer. Molecules. 2020; 25(14): 3146. https://doi.org/10.3390/molecules25143146.
  • Minnelli C., Cianfruglia L., Laudadio E., Mobbili G., Galeazzi R., Armeni T. Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer. Int J Mol Sci. 2021; 22(21). https://doi.org/10.3390/ijms222111833.
  • Della Via F.I., Shiraishi R.N., Santos I., Ferro K.P., SalazarTerreros M.J., Franchi Junior G.C., Rego E.M., Saad S.T.O., Torello C.O. (-)-Epigallocatechin-3-gallate induces apoptosis and differentiation in leukaemia by targeting reactive oxygen species and PIN1. Sci Rep. 2021; 11(1). https://doi.org/10.1038/s41598-021-88478-z.
  • Sheng J., Shi W., Guo H., Long W., Wang Y., Qi J., Liu J., Xu Y. The Inhibitory Effect of (-)-Epigallocatechin-3-Gallate on Breast Cancer Progression via Reducing SCUBE2 Methylation and DNMT Activity. Molecules. 2019; 24(16). https://doi.org/10.3390/molecules24162899.
  • Khan M.A., Hussain A., Sundaram M.K., Alalami U., Gunasekera D., Ramesh L., Hamza A., Quraishi U. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells. Oncol Rep. 2015; 33(4): 1976-84. https://doi.org/10.3892/or.2015.3802.
  • Nandakumar V., Vaid M., Katiyar S.K. (-)-Epigallocatechin3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis. 2011; 32(4): 537-44. https://doi.org/10.1093/carcin/bgq285.
  • Alizadeh M., Nafari A., Safarzadeh A., Veiskarami S., Almasian M., Asghar Kiani A. The Impact of EGCG and RG108 on SOCS1 Promoter DNA Methylation and Expression in U937 Leukemia Cells. Rep Biochem Mol Biol. 2021; 10(3): 455-61. https://doi.org/10.52547/rbmb.10.3.455.
  • Khan M.I., Nur S.M., Abdulaal W.H. A study on DNA methylation modifying natural compounds identified EGCG for induction of IFI16 gene expression related to the innate immune response in cancer cells. Oncol Lett. 2022; 24(1): 218. https://doi.org/10.3892/ol.2022.13339.
  • Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., Welsh W., Yang C.S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003; 63(22): 7563-70.
  • Chen L.L., Han W.F., Geng Y., Su J.S. A genome-wide study of DNA methylation modified by epigallocatechin-3-gallate in the CAL-27 cell line. Mol Med Rep. 2015; 12(4): 5886-90. https://doi.org/10.3892/mmr.2015.4118.
  • McLarty J., Bigelow R.L., Smith M., Elmajian D., Ankem M., Cardelli J.A. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2009; 2(7): 673-82. https://doi.org/10.1158/1940-6207.CAPR-08-0167.
  • Jazvinšćak Jembrek M., Oršolić N., Mandić L., Sadžak A., Šegota S. Anti-Oxidative, Anti-Inflammatory and Anti-Apoptotic Effects of Flavonols: Targeting Nrf2, NF-κB and p53 Pathways in Neurodegeneration. Antioxidants (Basel). 2021; 10(10). https://doi.org/10.3390/antiox10101628.
  • Jia S., Xu X., Zhou S., Chen Y., Ding G., Cao L. Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Cell Death Dis. 2019; 10(2). https://doi.org/10.1038/s41419-019-1366-y. Erratum in: Cell Death Dis. 2024; 15(1). https://doi.org/10.1038/s41419-023-06399-3.
  • Mukhtar E., Adhami V.M., Sechi M., Mukhtar H. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells. Cancer Lett. 2015; 367(2): 173-83. https://doi.org/10.1016/j.canlet.2015.07.030.
  • Hassan F.U., Rehman M.S., Khan M.S., Ali M.A., Javed A., Nawaz A., Yang C. Curcumin as an Alternative Epigenetic Modulator: Mechanism of Action and Potential Effects. Front Genet. 2019; 10. https://doi.org/10.3389/fgene.2019.00514.
  • Kirsanov K.I., Vlasova O.A., Fetisov T.I., Zenkov R.G., Lesovaya E.A., Belitskii G.A., Gurova K., Yakubovskaya M.G. Vliyanie DNKtropnykh antikantserogennykh soedinenii na mekhanizmy regulyatsii ekspressii genov. Uspekhi molekulyarnoi onkologii. 2018; 5(4): 41-63. https://doi.org/10.17650/2313-805X-2018-5-4-41-63.
  • Yu J., Peng Y., Wu L.C., Xie Z., Deng Y., Hughes T., He S., Mo X., Chiu M., Wang Q.E., He X., Liu S., Grever M.R., Chan K.K., Liu Z. Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. PLoS One. 2013; 8(2). https://doi.org/10.1371/ journal.pone.0055934.
  • Chen J., Ying Y., Zhu H., Zhu T., Qu C., Jiang J., Fang B. Curcumininduced promoter hypermethylation of the mammalian target of rapamycin gene in multiple myeloma cells. Oncol Lett. 2019; 17(1): 1108-14. https://doi.org/10.3892/ol.2018.9662.
  • Al-Yousef N., Shinwari Z., Al-Shahrani B., Al-Showimi M., AlMoghrabi N. Curcumin induces re-expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines. Oncol Rep. 2020; 43(3): 827-38. https://doi.org/10.3892/or.2020.7473.
  • Link A., Balaguer F., Shen Y., Lozano J.J., Leung H.C., Boland C.R., Goel A. Curcumin modulates DNA methylation in colorectal cancer cells. PLoS One. 2013; 8(2). https://doi.org/10.1371/journal.pone.0057709.
  • Hosokawa M., Seiki R., Iwakawa S., Ogawara K.I. Combination of azacytidine and curcumin is a potential alternative in decitabineresistant colorectal cancer cells with attenuated deoxycytidine kinase. Biochem Biophys Res Commun. 2021; 578: 157-62. https://doi.org/10.1016/j.bbrc.2021.09.041.
  • Howells L.M., Iwuji C.O.O., Irving G.R.B., Barber S., Walter H., Sidat Z., Griffin-Teall N., Singh R., Foreman N., Patel S.R., Morgan B., Steward W.P., Gescher A., Thomas A.L., Brown K. Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. J Nutr. 2019; 149(7): 1133-9. https://doi.org/10.1093/jn/nxz029.
  • Saghatelyan T., Tananyan A., Janoyan N., Tadevosyan A., Petrosyan H., Hovhannisyan A., Hayrapetyan L., Arustamyan M., Arnhold J., Rotmann A.R., Hovhannisyan A., Panossian A. Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial. Phytomedicine. 2020; 70. https://doi.org/10.1016/j.phymed.2020.153218.
  • Rauf A., Imran M., Suleria H.A.R., Ahmad B., Peters D.G., Mubarak M.S. A comprehensive review of the health perspectives of resveratrol. Food Funct. 2017; 8(12): 4284-305. https://doi.org/10.1039/c7fo01300k.
  • Aldawsari F.S., Aguayo-Ortiz R., Kapilashrami K., Yoo J., Luo M., Medina-Franco J.L., Velázquez-Martínez C.A. Resveratrolsalicylate derivatives as selective DNMT3 inhibitors and anticancer agents. J Enzyme Inhib Med Chem. 2016; 31(5): 695-703. https://doi.org/10.3109/14756366.2015.1058256.
  • Izquierdo-Torres E., Hernández-Oliveras A., Meneses-Morales I., Rodríguez G., Fuentes-García G., Zarain-Herzberg Á. Resveratrol upregulates ATP2A3 gene expression in breast cancer cell lines through epigenetic mechanisms. Int J Biochem Cell Biol. 2019; 113: 37-47. https://doi.org/10.1016/j.biocel.2019.05.020.
  • Sharifi-Rad J., Quispe C., Imran M., Rauf A., Nadeem M., Gondal T.A., Ahmad B., Atif M., Mubarak M.S., Sytar O., Zhilina O.M., Garsiya E.R., Smeriglio A., Trombetta D., Pons D.G., Martorell M., Cardoso S.M., Razis A.F.A., Sunusi U., Kamal R.M., Rotariu L.S., Butnariu M., Docea A.O., Calina D. Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits. Oxid Med Cell Longev. 2021. https://doi.org/10.1155/2021/3268136.
  • Sundaram M.K., Ansari M.Z., Al Mutery A., Ashraf M., Nasab R., Rai S., Rais N., Hussain A. Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells. Anticancer Agents Med Chem. 2018; 18(3): 412-21. https://doi.org/10.2174/1871520617666170918142114.
  • Sharma M., Tollefsbol T.O. Combinatorial epigenetic mechanisms of sulforaphane, genistein and sodium butyrate in breast cancer inhibition. Exp Cell Res. 2022; 416(1). https://doi.org/10.1016/j.yexcr.2022.113160.
  • Xie Q., Bai Q., Zou L.Y., Zhang Q.Y., Zhou Y., Chang H., Yi L., Zhu J.D., Mi M.T. Genistein inhibits DNA methylation and increases expression of tumor suppressor genes in human breast cancer cells. Genes Chromosomes Cancer. 2014; 53(5): 422-31. https://doi.org/10.1002/gcc.22154.
  • Romagnolo D.F., Donovan M.G., Papoutsis A.J., Doetschman T.C., Selmin O.I. Genistein Prevents BRCA1 CpG Methylation and Proliferation in Human Breast Cancer Cells with Activated Aromatic Hydrocarbon Receptor. Curr Dev Nutr. 2017; 1(6). https://doi.org/10.3945/cdn.117.000562.
  • Li H., Xu W., Huang Y., Huang X., Xu L., Lv Z. Genistein demethylates the promoter of CHD5 and inhibits neuroblastoma growth in vivo. Int J Mol Med. 2012; 30(5): 1081-6. https://doi.org/10.3892/ijmm.2012.1118.
  • Pintova S., Dharmupari S., Moshier E., Zubizarreta N., Ang C., Holcombe R.F. Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. Cancer Chemother Pharmacol. 2019; 84(3): 591-8. https://doi.org/10.1007/s00280-019-03886-3.
  • Chua G.N.L., Wassarman K.L., Sun H., Alp J.A., Jarczyk E.I., Kuzio N.J., Bennett M.J., Malachowsky B.G., Kruse M., Kennedy A.J. Cytosine-Based TET Enzyme Inhibitors. ACS Med Chem Lett. 2019; 10(2): 180-5. https://doi.org/10.1021/acsmedchemlett.8b00474.
  • Weirath N.A., Hurben A.K., Chao C., Pujari S.S., Cheng T., Liu S., Tretyakova N.Y. Small Molecule Inhibitors of TET Dioxygenases: Bobcat339 Activity Is Mediated by Contaminating Copper(II). ACS Med Chem Lett. 2022; 13(5): 792-8. https://doi.org/10.1021/acsmedchemlett.1c00677.
  • Singh A.K., Zhao B., Liu X., Wang X., Li H., Qin H., Wu X., Ma Yu., Horne D., Yu X. Selective targeting of TET catalytic domain promotes somatic cell reprogramming. Proc Natl Acad Sci U S A. 2020; 117(7): 3621-6. https://doi.org/10.1073/pnas.1910702117.
  • Guan Y., Tiwari A.D., Phillips J.G., Hasipek M., Grabowski D.R., Pagliuca S., Gopal P., Kerr C.M., Adema V., Radivoyevitch T., Parker Y., Lindner D.J., Meggendorfer M., Abazeed M., Sekeres M.A., Mian O.Y., Haferlach T., Maciejewski J.P., Jha B.K. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms. Blood Cancer Discov. 2021; 2(2): 146-61. https://doi.org/10.1158/2643-3230.BCD-20-0173.
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp